Abstract
Objectives: Plasma uracil is a new biomarker to assess the activity of dihydropyrimidine dehydrogenase before cancer treatment with fluoropyrimidine drugs. Knowledge on the biological variation of plasma uracil is important to assess the applicability of plasma uracil as a biomarker of drug tolerance and efficacy. Methods: A total of 33 apparently healthy individuals were submitted to sequential blood draws for three days. On the second day, blood draws were performed every third hour for 12 h. Plasma uracil was quantified by LC-MS/MS. The within-subject (CVI) and between-subject (CVG) biological variation estimates were calculated using linear mixed-effects models. Results: The overall median value of plasma uracil was 10.6 ng/mL (range 5.6-23.1 ng/mL). The CVI and CVG were 13.5 and 22.1%, respectively. Plasma uracil remained stable during the day, and there was no day-to-day variation observed. No differences in biological variation components were found between sex and no correlation to age was found. Four samples were calculated to be required to estimate the homeostatic set-point ±15% with 95% confidence. Conclusions: Plasma uracil is subject to tight homeostatic regulation without semidiurnal and day-to-day variation, however between-subject variation exists. This emphasizes plasma uracil as a well-suited biomarker for evaluation of dihydropyrimidine dehydrogenase activity, but four samples are required to establish the homeostatic set-point in a patient.
| Original language | English |
|---|---|
| Journal | Clinical Chemistry and Laboratory Medicine |
| Volume | 61 |
| Issue | 8 |
| Pages (from-to) | 1490-1496 |
| Number of pages | 7 |
| ISSN | 1434-6621 |
| DOIs | |
| Publication status | Published - Jul 2023 |
Keywords
- 5-fluorouracil
- biological variation
- dihydropyrimidine dehydrogenase (DPD) deficiency
- uracil
- Tandem Mass Spectrometry
- Humans
- Chromatography, Liquid
- Biomarkers
- Uracil
- Dihydrouracil Dehydrogenase (NADP)
- Fluorouracil